These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17172656)

  • 1. Oncogenes are to lose control on signaling following mutation: should we aim off target?
    Hornberg JJ; Westerhoff HV
    Mol Biotechnol; 2006 Oct; 34(2):109-16. PubMed ID: 17172656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
    Zhang Z; Li M; Rayburn ER; Hill DL; Zhang R; Wang H
    Am J Pharmacogenomics; 2005; 5(4):247-57. PubMed ID: 16078861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic signaling pathways and deregulated target genes.
    Schäfer R; Schramme A; Tchernitsa OI; Sers C
    Recent Results Cancer Res; 2007; 176():7-24. PubMed ID: 17607912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
    Amundadottir LT; Leder P
    Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TORgeting oncogene addiction for cancer therapy.
    Choo AY; Blenis J
    Cancer Cell; 2006 Feb; 9(2):77-9. PubMed ID: 16473275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
    Sharma SV; Fischbach MA; Haber DA; Settleman J
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4392s-4395s. PubMed ID: 16857816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
    J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene suppression by small interfering RNAs.
    Heidenreich O
    Curr Pharm Biotechnol; 2004 Aug; 5(4):349-54. PubMed ID: 15320765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase signaling networks in cancer.
    Brognard J; Hunter T
    Curr Opin Genet Dev; 2011 Feb; 21(1):4-11. PubMed ID: 21123047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogene addiction: role of signal attenuation.
    Hübner A; Jaeschke A; Davis RJ
    Dev Cell; 2006 Dec; 11(6):752-4. PubMed ID: 17141149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.
    Zhang Z; Li M; Rayburn ER; Hill DL; Zhang R; Wang H
    Am J Pharmacogenomics; 2005; 5(3):173-90. PubMed ID: 15952871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The good oncogene: When bad genes identify good outcome in cancer.
    Lee JM
    Med Hypotheses; 2011 Feb; 76(2):259-63. PubMed ID: 21050670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer biology: signatures guide drug choice.
    Downward J
    Nature; 2006 Jan; 439(7074):274-5. PubMed ID: 16421553
    [No Abstract]   [Full Text] [Related]  

  • 15. Kinase mutations in cancer: chinks in the enemy's armour?
    Di Nicolantonio F; Bardelli A
    Curr Opin Oncol; 2006 Jan; 18(1):69-76. PubMed ID: 16357567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling the Oncogenic Engine.
    Schambach A; Schott JW; Morgan MA
    Cancer Res; 2017 Nov; 77(22):6060-6064. PubMed ID: 29097608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
    Jiang BH; Liu LZ
    Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What makes oncogenes mutually exclusive?
    Cisowski J; Bergo MO
    Small GTPases; 2017 Jul; 8(3):187-192. PubMed ID: 27416373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated kinase screening identifies the
    Leonardi M; Perna E; Tronnolone S; Colecchia D; Chiariello M
    Autophagy; 2019 Feb; 15(2):312-326. PubMed ID: 30289335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretical mechanisms for synthesis of carcinogen-induced embryonic proteins: XIV. Mutational and non-mutational mechanisms as subsets of a more general mechanism. Part C. A defined cancer mutation.
    Hancock RL
    Med Hypotheses; 1985 Nov; 18(3):199-206. PubMed ID: 3853079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.